Burosumab in Unidentifiable Tumor‐Induced Osteomalacia [PDF]
Clinical Case ReportsTumor‐induced osteomalacia (TIO) can be challenging due to underlying tumors being either unresectable or unidentifiable. Burosumab, an anti‐FGF23 monoclonal antibody, has been proven to be effective in treating TIO but is currently not subsidized for ...
Yi Shan Der +5 more
doaj +5 more sources
Burosumab for adults with tumor-induced osteomalacia in China [PDF]
Endocrine ConnectionsA better understanding of the benefit of burosumab for treating tumor-induced osteomalacia (TIO) in Chinese patients is needed. The objective of this open-label, multicenter, single-cohort, post-marketing phase 4 study was to assess the efficacy ...
Ruizhi Jiajue +7 more
doaj +4 more sources
Effects of burosumab on macrophage polarization and TRPV1 expression in children with XLH [PDF]
Endocrine ConnectionsPurpose: X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by PHEX mutations, leading to hypophosphatemia and impaired bone mineralization.
Alessandra Di Paola +11 more
doaj +2 more sources
Frontiers in Endocrinology, 2023 Given the relatively recent introduction of burosumab in the management of X-linked hypophosphatemia (XLH), there is limited real-world data to guide its use in clinical practice.
Nick Shaw +2 more
exaly +3 more sources
Burosumab improves alkaline phosphatase and rickets severity in X-linked hypophosphatemia: 3-year SUNFLOWER analysis [PDF]
Bone ReportsSUNFLOWER is a 10-year longitudinal observational cohort study of patients with X-linked hypophosphatemia (XLH) in Japan and South Korea. This report describes the 3-year cut-off of SUNFLOWER, including data from 1 year of burosumab administration ...
Keiichi Ozono +10 more
doaj +2 more sources
Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
JBMR Plus, 2022 X‐linked hypophosphatemia (XLH) is a rare genetic disorder that disrupts skeletal and dental mineralization. In addition to rickets in children, XLH patients also have frequent spontaneous dental abscesses that increase the risk of tooth loss and may ...
Margaux Gadion +8 more
doaj +5 more sources
Prolonged neonatal phosphate retention and transient hypercalcemia following antenatal Burosumab exposure: a pharmacovigilance alert [PDF]
Therapeutic Advances in Drug SafetyBurosumab is a monoclonal antibody targeting fibroblast growth factor 23 (FGF23) and is approved for the treatment of X-linked hypophosphatemia. Its use during pregnancy has not been studied, and fetal exposure may affect neonatal mineral metabolism.
Guido Filler +4 more
doaj +2 more sources
Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia [PDF]
Frontiers in EndocrinologyBurosumab, a monoclonal antibody that binds and inhibits FGF23 activity, was approved in 2018 for treatment of children and adults with X-linked hypophosphatemia (XLH), an X-linked dominant disorder due to increased serum fibroblast growth factor 23 ...
Robert Bandir +4 more
doaj +2 more sources
Therapeutic Advances in Endocrinology and Metabolism, 2021 Background: Burosumab, a recombinant anti-FGF23 monoclonal antibody, was recently introduced as a treatment for X-linked hypophosphatemia (XLH). Burosumab normalizes blood phosphate levels, thereby healing rickets, decreasing leg bowing, and reducing ...
Yael Lebenthal +2 more
exaly +2 more sources
A phase 2 trial of burosumab for treatment of fibroblast growth factor-23-mediated hypophosphatemia in children and adults with fibrous dysplasia [PDF]
Bone ResearchFibrous dysplasia (FD) is a rare disorder associated with fractures and deformities. FD lesions produce excess phosphaturic hormone fibroblast growth factor 23 (FGF23), leading to hyperphosphaturia in most patients, and hypophosphatemia in those with ...
Olivia de Jong +9 more
doaj +2 more sources